SUPPLEMENT

Q4 2024 — Financial disclosures

Q4 2024PDF · 10 pages1.1 MB
Merck & Co., Inc.
Financial Highlights Package
Fourth Quarter 2024
Table of Contents
Table 1: GAAP P&L...................................................................................1
Table 1a: GAAP P&L – Current Year and Prior Year by Quarter................2
Table 2a: GAAP to Non-GAAP Reconciliation 4Q24 and Dec YTD 24.......3
Table 2b: GAAP to Non-GAAP Reconciliation 4Q23 and Dec YTD 23.......4
Table 3: Sales - Current Year and Prior Year by Quarter..........................5
Table 3a: Sales – U.S. / International 4Q24................................................6
Table 3b: Sales – U.S. / International Dec YTD 24.. ..................................7
Table 3c: Sales – Pharmaceutical Geographic Split...................................8
Table 4: Other (Income) Expense ............................................................9

-- 1 of 10 --

Sales 	15,624	$ 	14,630	$ 	7% 	64,168	$ 	60,115	$ 	7%
Costs, Expenses and Other
Cost of sales 	3,828 	3,911 	-2% 	15,193 	16,126 	-6%
Selling, general and administrative 	2,864 	2,804 	2% 	10,816 	10,504 	3%
Research and development 	4,585 	9,628 	-52% 	17,938 	30,531 	-41%
Restructuring costs 	51 	255 	-80% 	309 	599 	-48%
Other (income) expense, net 	126 	78 	62% 	(24) 	466 	*
Income (Loss) Before Taxes 	4,170 	(2,046) 	* 	19,936 	1,889 	*
Income Tax Provision (Benefit) 	425 	(821) 	2,803 	1,512
Net Income (Loss) 	3,745 	(1,225) 	* 	17,133 	377 	*
Less: Net Income Attributable to Noncontrolling Interests 	2 	1 	16 	12
Net Income (Loss) Attributable to Merck & Co., Inc. 	3,743	$ 	(1,226)	$ 	* 	17,117	$ 	365	$ 	*
Earnings (Loss) per Common Share Assuming Dilution (1) 	1.48	$ 	(0.48)	$ 	* 	6.74	$ 	0.14	$ 	*
Average Shares Outstanding Assuming Dilution (1) 	2,537 	2,533 	2,541 	2,547
Tax Rate 	10.2% 	40.1% 	14.1% 	80.0%
* 100% or greater
(1) Because the company recorded a net loss in the fourth quarter of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming
dilution as the effect would have been anti-dilutive.
GAAP
% Change	Full Year
2024
Full Year
2023
GAAP
% Change
4Q24 	4Q23
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
1

-- 2 of 10 --

Sales 	15,775	$ 	16,112	$ 	16,657	$ 	15,624	$ 	64,168	$ 	14,487	$ 	15,035	$ 	15,962	$ 	14,630	$ 	60,115	$ 	7% 	7%
Costs, Expenses and Other
Cost of sales 	3,540 	3,745 	4,080 	3,828 	15,193 	3,926 	4,024 	4,264 	3,911 	16,126 	-2% 	-6%
Selling, general and administrative 	2,483 	2,739 	2,731 	2,864 	10,816 	2,479 	2,702 	2,519 	2,804 	10,504 	2% 	3%
Research and development 	3,992 	3,500 	5,862 	4,585 	17,938 	4,276 	13,321 	3,307 	9,628 	30,531 	-52% 	-41%
Restructuring costs 	123 	80 	56 	51 	309 	67 	151 	126 	255 	599 	-80% 	-48%
Other (income) expense, net 	(33) 	42 	(162) 	126 	(24) 	89 	172 	126 	78 	466 	62% 	*
Income (Loss) Before Taxes 	5,670 	6,006 	4,090 	4,170 	19,936 	3,650 	(5,335) 	5,620 	(2,046) 	1,889 	* 	*
Income Tax Provision (Benefit) 	903 	545 	929 	425 	2,803 	825 	637 	870 	(821) 	1,512
Net Income (Loss) 	4,767 	5,461 	3,161 	3,745 	17,133 	2,825 	(5,972) 	4,750 	(1,225) 	377 	* 	*
Less: Net Income Attributable to Noncontrolling Interests 	5 	6 	4 	2 	16 	4 	3 	5 	1 	12
Net Income (Loss) Attributable to Merck & Co., Inc. 	4,762	$ 	5,455	$ 	3,157	$ 	3,743	$ 	17,117	$ 	2,821	$ 	(5,975)	$ 	4,745	$ 	(1,226)	$ 	365	$ 	* 	*
Earnings (Loss) per Common Share Assuming Dilution (1) 	1.87	$ 	2.14	$ 	1.24	$ 	1.48	$ 	6.74	$ 	1.11	$ 	(2.35)	$ 	1.86	$ 	(0.48)	$ 	0.14	$ 	* 	*
Average Shares Outstanding Assuming Dilution (1) 	2,544 	2,544 	2,541 	2,537 	2,541 	2,551 	2,539 	2,546 	2,533 	2,547
Tax Rate 	15.9% 	9.1% 	22.7% 	10.2% 	14.1% 	22.6% 	-11.9% 	15.5% 	40.1% 	80.0%
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
Full Year
% Change
Table 1a
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF OPERATIONS - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
4Q
(1) Because the company recorded a net loss in the second quarter and the fourth quarter of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as
the effect would have been anti-dilutive.
2024
2Q 	3Q 	4Q 	Full Year	1Q 	1Q 	2Q 	3Q 	4Q 	Full Year
2023
2

-- 3 of 10 --

Fourth Quarter
Cost of sales 	3,828	$ 	701 	121 	822 	3,006	$
Selling, general and administrative 	2,864 	29 	16 	45 	2,819
Research and development 	4,585 	12 	(1) 	11 	4,574
Restructuring costs 	51 	51 	51 	–
Other (income) expense, net 	126 	(31) 	152 	121 	5
Income Before Taxes 	4,170 	(711) 	(187) 	(152) 	(1,050) 	5,220
Income Tax Provision (Benefit) 	425 	(111) (3) 	(17) (3) 	(33) (3) 	(260) (4) 	(421) 	846
Net Income 	3,745 	(600) 	(170) 	(119) 	260 	(629) 	4,374
Net Income Attributable to Merck & Co., Inc. 	3,743 	(600) 	(170) 	(119) 	260 	(629) 	4,372
Earnings per Common Share Assuming Dilution 	1.48	$ 	(0.23) 	(0.07) 	(0.04) 	0.10 	(0.24) 	1.72	$
Tax Rate 	10.2% 	16.2%
Full Year
Cost of sales 	15,193	$ 	2,409 	495 	2,904 	12,289	$
Selling, general and administrative 	10,816 	117 	83 	200 	10,616
Research and development 	17,938 	72 	1 	73 	17,865
Restructuring costs 	309 	309 	309 	–
Other (income) expense, net 	(24) 	(79) 	45 	(34) 	10
Income Before Taxes 	19,936 	(2,519) 	(888) 	(45) 	(3,452) 	23,388
Income Tax Provision (Benefit) 	2,803 	(461) (3) 	(135) (3) 	(10) (3) 	(519) (4) 	(1,125) 	3,928
Net Income 	17,133 	(2,058) 	(753) 	(35) 	519 	(2,327) 	19,460
Net Income Attributable to Merck & Co., Inc. 	17,117 	(2,058) 	(753) 	(35) 	519 	(2,327) 	19,444
Earnings per Common Share Assuming Dilution 	6.74	$ 	(0.81) 	(0.30) 	(0.01) 	0.21 	(0.91) 	7.65	$
Tax Rate 	14.1% 	16.8%
Only the line items that are affected by non-GAAP adjustments are shown.
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing
non-GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting
purposes and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The
non-GAAP information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to
acquisitions and divestitures. Amounts included in research and development expenses primarily reflect the amortization of intangible assets. Additionally, research and development expenses for the full year includes Animal Health
intangible asset impairment charges. Amounts included in other (income) expense, net, primarily reflect royalty income and a decrease in the estimated fair value measurement of liabilities for contingent consideration related to the prior
termination of the Sanofi-Pasteur MSD joint venture.
(2) Amounts primarily include employee separation costs, accelerated depreciation and asset impairments associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
(4) Represents benefits recorded in the fourth quarter and full year due to reductions in reserves for unrecognized income tax benefits resulting from the expiration of the statute of limitations for assessments related to federal income tax
return years. The benefit recognized in the fourth quarter relates to the 2020 federal tax return year and the benefit recognized for the full year relates to both the 2020 and 2019 federal tax return years.
MERCK & CO., INC.
FOURTH QUARTER AND FULL YEAR 2024 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Table 2a
Certain Other Items 	Adjustment Subtotal 	Non-GAAP
3

-- 4 of 10 --

Fourth Quarter
Cost of sales 	3,911	$ 	454 	117 	571 	3,340	$
Selling, general and administrative 	2,804 	24 	29 	53 	2,751
Research and development 	9,628 	790 	790 	8,838
Restructuring costs 	255 	255 	255 	–
Other (income) expense, net 	78 	(35) 	(61) 	(96) 	174
Loss Before Taxes 	(2,046) 	(1,233) 	(401) 	61 	(1,573) 	(473)
Income Tax Provision (Benefit) 	(821) 	(227) (4) 	(67) (4) 	13 (4) 	(281) 	(540)
Net (Loss) Income 	(1,225) 	(1,006) 	(334) 	48 	(1,292) 	67
Net (Loss) Income Attributable to Merck & Co., Inc. 	(1,226) 	(1,006) 	(334) 	48 	(1,292) 	66
(Loss) Earnings per Common Share Assuming Dilution (5) 	(0.48)	$ 	(0.40) 	(0.13) 	0.02 	(0.51) 	0.03	$
Tax Rate 	40.1% 	114.2%
Full Year
Cost of sales 	16,126	$ 	2,018 	211 	2,229 	13,897	$
Selling, general and administrative 	10,504 	86 	122 	208 	10,296
Research and development 	30,531 	819 	1 	820 	29,711
Restructuring costs 	599 	599 	599 	–
Other (income) expense, net 	466 	(47) 	(279) 	573 (3) 	247 	219
Income Before Taxes 	1,889 	(2,876) 	(933) 	279 	(573) 	(4,103) 	5,992
Income Tax Provision (Benefit) 	1,512 	(476) (4) 	(155) (4) 	60 (4) 	(60) (4) 	(631) 	2,143
Net Income 	377 	(2,400) 	(778) 	219 	(513) 	(3,472) 	3,849
Net Income Attributable to Merck & Co., Inc. 	365 	(2,400) 	(778) 	219 	(513) 	(3,472) 	3,837
Earnings per Common Share Assuming Dilution 	0.14	$ 	(0.94) 	(0.31) 	0.08 	(0.20) 	(1.37) 	1.51	$
Tax Rate 	80.0% 	35.8%
Only the line items that are affected by non-GAAP adjustments are shown.
(5) Because the company recorded a net loss in the fourth quarter of 2023, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive.
Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing non-
GAAP information enhances investors’ understanding of the company’s results because management uses non-GAAP measures to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes
and to measure the performance of the company along with other metrics. In addition, annual employee compensation, including senior management’s compensation, is derived in part using a non-GAAP pretax income metric. The non-GAAP
information presented should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.
(1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect integration, transaction and certain other costs related to acquisitions
and divestitures. Amounts included in research and development expenses primarily reflect a $779 million in-process research and development (IPR&D) impairment charge related to gefapixant and expenses for the amortization of intangible
assets. Amounts included in other (income) expense, net, primarily reflect royalty income related to the prior termination of the Sanofi-Pasteur MSD joint venture. Additionally, other (income) expense, net, for the full year includes a $37 million loss
on the sale of a business.
(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.
(3) Reflects a charge related to settlements with certain plaintiffs in the Zetia antitrust litigation.
(4) Represents the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.
Adjustment Subtotal 	Non-GAAP
MERCK & CO., INC.
FOURTH QUARTER AND FULL YEAR 2023 GAAP TO NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2b
GAAP 	Acquisition and Divestiture-
Related Costs (1) 	Restructuring Costs (2)	
(Income) Loss from
Investments in Equity
Securities
Certain Other Items
4

-- 5 of 10 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3
2024 	2023 	4Q 	Full Year
1Q 	2Q 	3Q 	4Q 	Full Year 	1Q 	2Q 	3Q 	4Q 	Full Year 	Nom % Ex-Exch % 	Nom % Ex-Exch %
TOTAL SALES (1) 	$15,775 	$16,112 	$16,657 	$15,624 	$64,168 	$14,487 	$15,035 	$15,962 	$14,630 	$60,115 	7 	9 	7 	10
PHARMACEUTICAL 	14,006 	14,408 	14,943 	14,042 	57,400 	12,721 	13,457 	14,263 	13,141 	53,583 	7 	8 	7 	10
Oncology
Keytruda 	6,947 	7,270 	7,429 	7,836 	29,482 	5,795 	6,271 	6,338 	6,608 	25,011 	19 	21 	18 	22
Alliance Revenue – Lynparza (2) 	292 	317 	337 	365 	1,311 	275 	310 	299 	315 	1,199 	16 	18 	9 	11
Alliance Revenue – Lenvima (2) 	255 	249 	251 	255 	1,010 	232 	242 	260 	226 	960 	13 	14 	5 	6
Welireg 	85 	126 	139 	160 	509 	42 	50 	54 	72 	218 	122 	123 	133 	133
Alliance Revenue – Reblozyl (3) 	71 	90 	100 	110 	371 	43 	47 	52 	70 	212 	58 	58 	75 	75
Vaccines (4)
Gardasil/Gardasil 9 	2,249 	2,478 	2,306 	1,550 	8,583 	1,972 	2,458 	2,585 	1,871 	8,886 	-17 	-18 	-3 	-2
ProQuad/M-M-R II/Varivax 	570 	617 	703 	594 	2,485 	528 	582 	713 	545 	2,368 	9 	9 	5 	5
Vaxneuvance 	219 	189 	239 	161 	808 	106 	168 	214 	176 	665 	-9 	-9 	22 	23
RotaTeq 	216 	163 	193 	139 	711 	297 	131 	156 	185 	769 	-25 	-25 	-8 	-7
Pneumovax 23 	61 	59 	68 	74 	263 	96 	92 	140 	85 	412 	-12 	-12 	-36 	-34
Hospital Acute Care
Bridion 	440 	455 	420 	449 	1,764 	487 	502 	424 	429 	1,842 	5 	5 	-4 	-3
Prevymis 	174 	188 	208 	215 	785 	129 	143 	157 	175 	605 	23 	23 	30 	33
Dificid 	73 	92 	96 	79 	340 	65 	76 	74 	87 	302 	-9 	-9 	13 	13
Zerbaxa 	56 	62 	64 	70 	252 	50 	54 	53 	61 	218 	14 	16 	16 	18
Noxafil 	56 	45 	41 	36 	177 	60 	55 	51 	46 	213 	-23 	-17 	-17 	-8
Cardiovascular
Winrevair 	70 	149 	200 	419 	- 	- 	- 	-
Alliance Revenue - Adempas/Verquvo (5) 	98 	106 	102 	109 	415 	99 	68 	92 	108 	367 	1 	1 	13 	13
Adempas (6) 	70 	72 	72 	73 	287 	59 	65 	65 	66 	255 	11 	9 	12 	14
Virology
Lagevrio 	350 	110 	383 	121 	964 	392 	203 	640 	193 	1,428 	-37 	-37 	-33 	-28
Isentress/Isentress HD 	111 	89 	102 	92 	394 	123 	136 	119 	105 	483 	-13 	-7 	-18 	-14
Delstrigo 	56 	60 	65 	69 	249 	44 	50 	54 	54 	201 	28 	29 	24 	26
Pifeltro 	42 	39 	42 	40 	163 	34 	38 	37 	33 	142 	20 	20 	15 	15
Neuroscience
Belsomra 	46 	53 	78 	45 	222 	56 	63 	58 	54 	231 	-17 	-17 	-4 	1
Immunology
Simponi 	184 	172 	189 	543 	180 	180 	179 	171 	710 	N/M 	N/M 	-24 	-23
Remicade 	39 	35 	41 	114 	51 	48 	45 	43 	187 	N/M 	N/M 	-39 	-36
Diabetes (7)
Januvia 	419 	405 	278 	232 	1,334 	551 	511 	581 	547 	2,189 	-58 	-56 	-39 	-36
Janumet 	251 	224 	204 	255 	935 	329 	354 	255 	240 	1,177 	7 	11 	-21 	-16
Other Pharmaceutical (8) 	576 	573 	644 	713 	2,510 	626 	560 	568 	576 	2,333 	25 	25 	8 	10
ANIMAL HEALTH 	1,511 	1,482 	1,487 	1,397 	5,877 	1,491 	1,456 	1,400 	1,278 	5,625 	9 	13 	4 	8
Livestock 	850 	837 	886 	889 	3,462 	849 	807 	874 	808 	3,337 	10 	14 	4 	9
Companion Animal 	661 	645 	601 	508 	2,415 	642 	649 	526 	470 	2,288 	8 	10 	6 	7
Other Revenues (9) 	258 	222 	227 	185 	891 	275 	122 	299 	211 	907 	-13 	3 	-2 	4
N/M - Not Meaningful
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(7) Total Diabetes sales were $745 million, $715 million, $592 million and $546 million in the first, second, third and fourth quarter of 2024, respectively, and $950 million, $951 million, $924 million
and $876 million in the first, second, third and fourth quarter of 2023, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues, including revenue-hedging activities. Other Revenues
related to the receipt of upfront and milestone payments for out-licensed products were $61 million, $15 million, $15 million and $15 million in the first, second, third and fourth quarter of 2024,
respectively, and $51 million, $3 million and $65 million in the first, second and third quarter of 2023, respectively.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $3,424 million, $3,656 million, $3,675 million and $2,693 million in the first, second, third and fourth quarter of 2024, respectively, and $3,133 million, $3,557 million,
$4,002 million and $2,962 million in the first, second, third and fourth quarter of 2023, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs.
(6) Net product sales in Merck's marketing territories.
5

-- 6 of 10 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FOURTH QUARTER 2024
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3a
Global 	U.S. 	International
4Q 2024 	4Q 2023 % Change 	4Q 2024 	4Q 2023 % Change 	4Q 2024 	4Q 2023 % Change
TOTAL SALES (1) 	$15,624 	$14,630 	7 	$8,188 	$7,088 	16 	$7,436 	$7,542 	-1
PHARMACEUTICAL 	14,042 	13,141 	7 	7,728 	6,698 	15 	6,314 	6,443 	-2
Oncology
Keytruda 	7,836 	6,608 	19 	4,841 	3,972 	22 	2,996 	2,636 	14
Alliance Revenue – Lynparza (2) 	365 	315 	16 	177 	168 	5 	187 	147 	28
Alliance Revenue – Lenvima (2) 	255 	226 	13 	182 	181 	1 	73 	45 	63
Welireg 	160 	72 	122 	146 	68 	114 	14 	4 	*
Alliance Revenue – Reblozyl (3) 	110 	70 	58 	88 	60 	47 	22 	10 	124
Vaccines (4)
Gardasil/Gardasil 9 	1,550 	1,871 	-17 	380 	365 	4 	1,170 	1,506 	-22
ProQuad/M-M-R II/Varivax 	594 	545 	9 	419 	402 	4 	175 	143 	23
Vaxneuvance 	161 	176 	-9 	64 	138 	-53 	96 	38 	153
RotaTeq 	139 	185 	-25 	84 	112 	-25 	55 	73 	-25
Pneumovax 23 	74 	85 	-12 	19 	22 	-13 	55 	62 	-12
Hospital Acute Care
Bridion 	449 	429 	5 	382 	315 	21 	67 	113 	-41
Prevymis 	215 	175 	23 	106 	78 	36 	109 	98 	12
Dificid 	79 	87 	-9 	72 	75 	-4 	7 	12 	-42
Zerbaxa 	70 	61 	14 	40 	33 	23 	30 	28 	4
Noxafil 	36 	46 	-23 	-2 	4 	-149 	37 	43 	-12
Cardiovascular
Winrevair 	200 	- 	192 	- 	9 	-
Alliance Revenue - Adempas/Verquvo (5) 	109 	108 	1 	105 	102 	3 	5 	6 	-27
Adempas (6) 	73 	66 	11 	73 	66 	11
Virology
Lagevrio 	121 	193 	-37 	32 	10 	* 	88 	183 	-52
Isentress/Isentress HD 	92 	105 	-13 	38 	50 	-23 	53 	56 	-4
Delstrigo 	69 	54 	28 	14 	12 	19 	55 	42 	30
Pifeltro 	40 	33 	20 	26 	23 	16 	13 	10 	29
Neuroscience
Belsomra 	45 	54 	-17 	19 	21 	-12 	26 	33 	-20
Immunology
Simponi 	171 	N/M 	171 	N/M
Remicade 	43 	N/M 	43 	N/M
Diabetes (7)
Januvia 	232 	547 	-58 	41 	309 	-87 	191 	239 	-20
Janumet 	255 	240 	7 	91 	41 	122 	164 	198 	-17
Other Pharmaceutical (8) 	713 	576 	25 	172 	137 	26 	544 	438 	24
ANIMAL HEALTH 	1,397 	1,278 	9 	444 	387 	15 	953 	891 	7
Livestock 	889 	808 	10 	203 	158 	28 	686 	649 	6
Companion Animal 	508 	470 	8 	241 	229 	5 	267 	242 	11
Other Revenues (9) 	185 	211 	-13 	16 	3 	* 	169 	208 	-19
*200% or greater
N/M - Not Meaningful
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $546 million and $876 million on a global basis in the fourth quarter of 2024 and 2023, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were $15
million on a global basis in the fourth quarter of 2024.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $2,693 million and $2,962 million on a global basis in the fourth quarter of 2024 and 2023, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and
commercialization costs.
6

-- 7 of 10 --

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
FULL YEAR 2024
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3b
Global 	U.S. 	International
Full Year
2024
Full Year
2023 	% Change 	Full Year 2024
Full Year
2023 	% Change
Full Year
2024
Full Year
2023 	% Change
TOTAL SALES (1) 	$64,168 	$60,115 	7 	$32,277 	$28,480 	13 	$31,891 	$31,635 	1
PHARMACEUTICAL 	57,400 	53,583 	7 	30,290 	26,539 	14 	27,110 	27,044 	-
Oncology
Keytruda 	29,482 	25,011 	18 	17,872 	15,114 	18 	11,610 	9,897 	17
Alliance Revenue – Lynparza (2) 	1,311 	1,199 	9 	626 	607 	3 	685 	592 	16
Alliance Revenue – Lenvima (2) 	1,010 	960 	5 	705 	657 	7 	305 	303 	1
Welireg 	509 	218 	133 	466 	209 	123 	43 	10 	*
Alliance Revenue – Reblozyl (3) 	371 	212 	75 	303 	168 	80 	68 	43 	56
Vaccines (4)
Gardasil/Gardasil 9 	8,583 	8,886 	-3 	2,425 	2,083 	16 	6,158 	6,803 	-9
ProQuad/M-M-R II/Varivax 	2,485 	2,368 	5 	1,919 	1,837 	4 	566 	531 	7
Vaxneuvance 	808 	665 	22 	461 	561 	-18 	347 	103 	*
RotaTeq 	711 	769 	-8 	472 	493 	-4 	239 	276 	-13
Pneumovax 23 	263 	412 	-36 	56 	127 	-56 	207 	285 	-27
Hospital Acute Care
Bridion 	1,764 	1,842 	-4 	1,401 	1,156 	21 	363 	686 	-47
Prevymis 	785 	605 	30 	371 	264 	41 	414 	341 	21
Dificid 	340 	302 	13 	303 	274 	10 	37 	28 	34
Zerbaxa 	252 	218 	16 	146 	119 	23 	106 	100 	7
Noxafil 	177 	213 	-17 	7 	32 	-78 	170 	181 	-6
Cardiovascular
Winrevair 	419 	- 	408 	- 	11 	-
Alliance Revenue - Adempas/Verquvo (5) 	415 	367 	13 	388 	350 	11 	27 	16 	65
Adempas (6) 	287 	255 	12 	287 	255 	12
Virology
Lagevrio 	964 	1,428 	-33 	176 	10 	* 	787 	1,418 	-44
Isentress/Isentress HD 	394 	483 	-18 	185 	215 	-14 	209 	268 	-22
Delstrigo 	249 	201 	24 	56 	49 	14 	193 	152 	27
Pifeltro 	163 	142 	15 	113 	101 	12 	50 	41 	22
Neuroscience
Belsomra 	222 	231 	-4 	72 	81 	-11 	150 	150 	-
Immunology
Simponi 	543 	710 	-24 	543 	710 	-24
Remicade 	114 	187 	-39 	114 	187 	-39
Diabetes (7)
Januvia 	1,334 	2,189 	-39 	469 	1,151 	-59 	865 	1,039 	-17
Janumet 	935 	1,177 	-21 	161 	223 	-28 	774 	954 	-19
Other Pharmaceutical (8) 	2,510 	2,333 	8 	729 	658 	11 	1,782 	1,675 	6
ANIMAL HEALTH 	5,877 	5,625 	4 	1,861 	1,804 	3 	4,016 	3,821 	5
Livestock 	3,462 	3,337 	4 	732 	700 	5 	2,729 	2,637 	3
Companion Animal 	2,415 	2,288 	6 	1,129 	1,104 	2 	1,287 	1,184 	9
Other Revenues (9) 	891 	907 	-2 	126 	137 	-8 	765 	770 	-1
*200% or greater
(6) Net product sales in Merck's marketing territories.
(7) Total Diabetes sales were $2,599 million and $3,701 million on a global basis for December YTD 2024 and 2023, respectively.
(8) Includes Pharmaceutical products not individually shown above.
(9) Other Revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities. Other Revenues related to the receipt of upfront and milestone payments for out-licensed products were
$106 million and $118 million on a global basis for December YTD 2024 and 2023, respectively.
Sum of U.S. plus international may not equal global due to rounding.
(1) Only select products are shown.
(2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs.
(3) Alliance Revenue represents royalties.
(4) Total Vaccines sales were $13,448 million and $13,654 million on a global basis for December YTD 2024 and 2023, respectively.
(5) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and
commercialization costs.
7

-- 8 of 10 --

MERCK & CO., INC.
PHARMACEUTICAL GEOGRAPHIC SALES
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 3c
2024 	2023 	% Change
1Q 	2Q 	3Q 	4Q 	Full Year 	1Q 	2Q 	3Q 	4Q 	Full Year 	4Q 	Full Year
TOTAL PHARMACEUTICAL 	$14,006 	$14,408 	$14,943 	$14,042 	$57,400 	$12,721 	$13,457 	$14,263 	$13,141 	$53,583 	7 	7
United States 	6,936 	7,399 	8,227 	7,728 	30,290 	6,117 	6,570 	7,153 	6,698 	26,539 	15 	14
% Pharmaceutical Sales 	49.5% 	51.4% 	55.1% 	55.0% 	52.8% 	48.1% 	48.8% 	50.1% 	51.0% 	49.5%
Europe (1) 	2,555 	2,572 	2,620 	2,498 	10,246 	2,326 	2,401 	2,497 	2,491 	9,715 	- 	5
% Pharmaceutical Sales 	18.2% 	17.9% 	17.5% 	17.8% 	17.9% 	18.3% 	17.8% 	17.5% 	19.0% 	18.1%
China 	1,744 	1,790 	996 	864 	5,394 	1,694 	1,887 	1,674 	1,456 	6,710 	-41 	-20
% Pharmaceutical Sales 	12.5% 	12.4% 	6.7% 	6.2% 	9.4% 	13.3% 	14.0% 	11.7% 	11.1% 	12.5%
Japan 	802 	664 	919 	813 	3,199 	737 	652 	1,062 	629 	3,081 	29 	4
% Pharmaceutical Sales 	5.7% 	4.6% 	6.2% 	5.8% 	5.6% 	5.8% 	4.8% 	7.4% 	4.8% 	5.7%
Latin America 	601 	661 	730 	680 	2,672 	470 	566 	696 	596 	2,328 	14 	15
% Pharmaceutical Sales 	4.3% 	4.6% 	4.9% 	4.8% 	4.7% 	3.7% 	4.2% 	4.9% 	4.5% 	4.3%
Asia Pacific (other than China and Japan) 	580 	595 	669 	612 	2,457 	703 	705 	636 	616 	2,661 	-1 	-8
% Pharmaceutical Sales 	4.1% 	4.1% 	4.5% 	4.4% 	4.3% 	5.5% 	5.2% 	4.5% 	4.7% 	5.0%
Eastern Europe/Middle East/Africa 	395 	353 	400 	348 	1,495 	381 	370 	301 	299 	1,351 	16 	11
% Pharmaceutical Sales 	2.8% 	2.4% 	2.7% 	2.5% 	2.6% 	3.0% 	2.7% 	2.1% 	2.3% 	2.5%
Canada 	138 	143 	133 	144 	558 	141 	127 	133 	138 	540 	4 	3
% Pharmaceutical Sales 	1.0% 	1.0% 	0.9% 	1.0% 	1.0% 	1.1% 	0.9% 	0.9% 	1.1% 	1.0%
Other 	255 	231 	249 	355 	1,089 	152 	179 	111 	218 	658 	63 	66
% Pharmaceutical Sales 	1.9% 	1.6% 	1.5% 	2.5% 	1.7% 	1.2% 	1.6% 	0.9% 	1.5% 	1.4%
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom.
8

-- 9 of 10 --

OTHER (INCOME) EXPENSE, NET
4Q24 	4Q23
Full Year
2024
Full Year
2023
Interest income 	(146)	$ 	(70)	$ 	(415)	$ 	(365)	$
Interest expense 	328 	310 	1,271 	1,146
Exchange losses 	49 	162 	227 	370
Loss (income) from investments in equity securities, net (1) 	156 	(99) 	(14) 	(340)
Net periodic defined benefit plan (credit) cost other than service cost 	(157) 	(134) 	(633) 	(498)
Other, net 	(104) 	(91) 	(460) 	153
Total 	126	$ 	78	$ 	(24)	$ 	466	$
(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment
funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from
ownership interests in investment funds are accounted for on a one quarter lag.
MERCK & CO., INC.
OTHER (INCOME) EXPENSE, NET - GAAP
(AMOUNTS IN MILLIONS)
(UNAUDITED)
Table 4
9

-- 10 of 10 --